INVESTORS

Axela provides products that accelerate the validation of protein biomarkers from discovery into routine clinical use. Our proprietary technology, Diffractive Optics Technology (dot™), enables the real-time detection and quantitation of protein binding events in complex media. This technology is incorporated into the dotLab™ System, a bench-top platform that delivers simple, affordable, yet highly sensitive protein based assays. Future products targeting underserved diagnostic markets including point of care (POC) markets are also planned.

Axela is a privately-held company based in Toronto, Ontario and is well funded by some of Canada's most reputable venture capital firms. The company's intellectual property position includes over 150 exclusive patents and applications. Axela was selected as one of Canada's Top 10 Investment Prospects for Life Science Companies in 2005/2006.

For further inquiries, please contact Owen Gordon at:

Axela Inc.
480 University Avenue
Suite 910
Toronto, ON M5G 1V2
Canada

Phone: 416-260-3103
Toll Free:  866-94-AXELA
Fax: 416-260-9255

No email inquiries, please.